Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Aaron L. Ellenbogen"'
Autor:
Nicola L. Brice, Mark Carlton, David H. Margolin, Martin Bexon, Kim L. Matthews, Lee A. Dawson, Aaron L. Ellenbogen, C. Warren Olanow, Jordan Dubow, Karl Kieburtz
Publikováno v:
EClinicalMedicine, Vol 77, Iss , Pp 102882- (2024)
Summary: Background: CVN424 is a GPR6 inverse agonist that provides selective pharmacological control of the indirect striatopallidal pathway. We assessed the safety and efficacy of CVN424 as an adjunctive treatment to levodopa for reducing OFF-time
Externí odkaz:
https://doaj.org/article/03ffbbb6c9d240da9bd6c36037040312
Autor:
Gerard E. Francisco, George F. Wittenberg, Aleksej Zuzek, Tricia Fleming, Kenneth Ngo, Alberto Esquenazi, Joan Largent, Wolfgang H. Jost, Aaron L. Ellenbogen
Publikováno v:
Archives of Physical Medicine and Rehabilitation. 100:e104
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::614bde51d0c785053d2df34a934a8d45
https://doi.org/10.1016/j.apmr.2019.08.300
https://doi.org/10.1016/j.apmr.2019.08.300
Autor:
William G. Ondo, Clete A. Kushida, Sarah Kavanagh, Aaron L. Ellenbogen, Christine K. Caivano, Philip M. Becker, Eric Ball, Richard K. Bogan
Publikováno v:
Journal of Parkinsonism and Restless Legs Syndrome.
Richard K Bogan,1 Aaron Ellenbogen,2 Philip M Becker,3 Clete Kushida,4 Eric Ball,5 William G Ondo,6 Christine K Caivano,7 Sarah Kavanagh71SleepMed, Columbia, SC, 2Quest Research Institute, Farmington Hills, MI, 3Sleep Medicine Associates of Texas, Da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e52094c114fe4fe495b60ccd5f1f8f08
https://www.dovepress.com/gabapentin-enacarbil-in-subjects-with-moderate-to-severe-primary-restl-peer-reviewed-article-JPRLS
https://www.dovepress.com/gabapentin-enacarbil-in-subjects-with-moderate-to-severe-primary-restl-peer-reviewed-article-JPRLS
Autor:
Kenneth C. Cundy, Harisha Atluri, Wendy Luo, Daniel Bonzo, Janet Hurt, Katie Zomorodi, Amanda Vu, Ritu Lal, Marie-Liesse Lassauzet Lassauzet, Dan Chen, Aaron L. Ellenbogen, James Tovera
Publikováno v:
Clinical neuropharmacology. 35(4)
OBJECTIVE The objective of this study was to determine steady-state gabapentin exposures and corresponding relief of symptoms and safety profile produced by 4 dose levels of gabapentin enacarbil (GEn) in subjects with restless legs syndrome (RLS). ME
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0766615ff51af91ded825b4b64ff378e
https://pubmed.ncbi.nlm.nih.gov/22664749
https://pubmed.ncbi.nlm.nih.gov/22664749
Autor:
Philip M. Becker, Dan Chen, Aaron L. Ellenbogen, Marie-Liesse Lassauzet, David Winslow, Jerry M. Tolson, Stephen G. Thein
Publikováno v:
Clinical neuropharmacology. 34(1)
OBJECTIVES This open-label, multicenter, 52-week extension study (NCT00333359) assessed the long-term safety and efficacy of gabapentin enacarbil in subjects with moderate-to-severe primary restless legs syndrome (RLS). METHODS Subjects had completed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14e660db7e31dfdcfa55e7794e3a46f3
https://pubmed.ncbi.nlm.nih.gov/21242741
https://pubmed.ncbi.nlm.nih.gov/21242741